Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis.
Cardiovascular disease
Meta-analysis
Prediction models
Prognosis
Systematic review
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
13 06 2019
13 06 2019
Historique:
received:
05
02
2019
accepted:
07
05
2019
entrez:
14
6
2019
pubmed:
14
6
2019
medline:
27
11
2019
Statut:
epublish
Résumé
The Framingham risk models and pooled cohort equations (PCE) are widely used and advocated in guidelines for predicting 10-year risk of developing coronary heart disease (CHD) and cardiovascular disease (CVD) in the general population. Over the past few decades, these models have been extensively validated within different populations, which provided mounting evidence that local tailoring is often necessary to obtain accurate predictions. The objective is to systematically review and summarize the predictive performance of three widely advocated cardiovascular risk prediction models (Framingham Wilson 1998, Framingham ATP III 2002 and PCE 2013) in men and women separately, to assess the generalizability of performance across different subgroups and geographical regions, and to determine sources of heterogeneity in the findings across studies. A search was performed in October 2017 to identify studies investigating the predictive performance of the aforementioned models. Studies were included if they externally validated one or more of the original models in the general population for the same outcome as the original model. We assessed risk of bias for each validation and extracted data on population characteristics and model performance. Performance estimates (observed versus expected (OE) ratio and c-statistic) were summarized using a random effects models and sources of heterogeneity were explored with meta-regression. The search identified 1585 studies, of which 38 were included, describing a total of 112 external validations. Results indicate that, on average, all models overestimate the 10-year risk of CHD and CVD (pooled OE ratio ranged from 0.58 (95% CI 0.43-0.73; Wilson men) to 0.79 (95% CI 0.60-0.97; ATP III women)). Overestimation was most pronounced for high-risk individuals and European populations. Further, discriminative performance was better in women for all models. There was considerable heterogeneity in the c-statistic between studies, likely due to differences in population characteristics. The Framingham Wilson, ATP III and PCE discriminate comparably well but all overestimate the risk of developing CVD, especially in higher risk populations. Because the extent of miscalibration substantially varied across settings, we highly recommend that researchers further explore reasons for overprediction and that the models be updated for specific populations.
Sections du résumé
BACKGROUND
The Framingham risk models and pooled cohort equations (PCE) are widely used and advocated in guidelines for predicting 10-year risk of developing coronary heart disease (CHD) and cardiovascular disease (CVD) in the general population. Over the past few decades, these models have been extensively validated within different populations, which provided mounting evidence that local tailoring is often necessary to obtain accurate predictions. The objective is to systematically review and summarize the predictive performance of three widely advocated cardiovascular risk prediction models (Framingham Wilson 1998, Framingham ATP III 2002 and PCE 2013) in men and women separately, to assess the generalizability of performance across different subgroups and geographical regions, and to determine sources of heterogeneity in the findings across studies.
METHODS
A search was performed in October 2017 to identify studies investigating the predictive performance of the aforementioned models. Studies were included if they externally validated one or more of the original models in the general population for the same outcome as the original model. We assessed risk of bias for each validation and extracted data on population characteristics and model performance. Performance estimates (observed versus expected (OE) ratio and c-statistic) were summarized using a random effects models and sources of heterogeneity were explored with meta-regression.
RESULTS
The search identified 1585 studies, of which 38 were included, describing a total of 112 external validations. Results indicate that, on average, all models overestimate the 10-year risk of CHD and CVD (pooled OE ratio ranged from 0.58 (95% CI 0.43-0.73; Wilson men) to 0.79 (95% CI 0.60-0.97; ATP III women)). Overestimation was most pronounced for high-risk individuals and European populations. Further, discriminative performance was better in women for all models. There was considerable heterogeneity in the c-statistic between studies, likely due to differences in population characteristics.
CONCLUSIONS
The Framingham Wilson, ATP III and PCE discriminate comparably well but all overestimate the risk of developing CVD, especially in higher risk populations. Because the extent of miscalibration substantially varied across settings, we highly recommend that researchers further explore reasons for overprediction and that the models be updated for specific populations.
Identifiants
pubmed: 31189462
doi: 10.1186/s12916-019-1340-7
pii: 10.1186/s12916-019-1340-7
pmc: PMC6563379
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
109Références
BMC Cardiovasc Disord. 2019 Jan 9;19(1):11
pubmed: 30626326
Circulation. 2014 Jan 14;129(2):266-7
pubmed: 24334111
Eur Heart J. 2014 Aug 1;35(29):1925-31
pubmed: 24898551
Prim Care. 1995 Jun;22(2):341-63
pubmed: 7617791
J Epidemiol Community Health. 2019 Jan;73(1):19-25
pubmed: 30262553
BMJ Open. 2014 May 21;4(5):e005025
pubmed: 24848088
Am J Cardiol. 2017 Mar 15;119(6):881-885
pubmed: 28061997
Am J Cardiol. 2004 Jul 1;94(1):20-4
pubmed: 15219502
J Am Heart Assoc. 2015 Apr 17;4(4):
pubmed: 25888372
Circulation. 2002 Dec 17;106(25):3143-421
pubmed: 12485966
Circulation. 1998 May 12;97(18):1837-47
pubmed: 9603539
Rev Esp Cardiol. 2007 Jul;60(7):693-702
pubmed: 17663853
Eur J Cardiovasc Prev Rehabil. 2010 Apr;17(2):244-9
pubmed: 20195155
Ann Intern Med. 2019 Jan 1;170(1):51-58
pubmed: 30596875
Am J Cardiol. 2007 May 1;99(9):1236-41
pubmed: 17478150
Stat Methods Med Res. 2018 Nov;27(11):3505-3522
pubmed: 28480827
BMJ. 2017 May 23;357:j2099
pubmed: 28536104
Ann Intern Med. 2015 Jul 7;163(1):68
pubmed: 26148286
Ann Intern Med. 2016 Dec 6;165(11):786-794
pubmed: 27723890
Int J Epidemiol. 2005 Apr;34(2):413-21
pubmed: 15659467
Int J Cardiol. 2010 Sep 3;143(3):385-90
pubmed: 19386372
Atherosclerosis. 2015 Sep;242(1):367-75
pubmed: 26255683
BMJ. 2016 Jun 22;353:i3140
pubmed: 27334381
Circulation. 2014 Jan 14;129(2):268-9
pubmed: 24334112
Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004816
pubmed: 23440795
J Am Coll Cardiol. 2015 Dec 22;66(24):2699-2709
pubmed: 26700832
Am Heart J. 2007 May;153(5):722-31, 731.e1-8
pubmed: 17452145
Arch Intern Med. 2008 Jun 9;168(11):1209-16
pubmed: 18541829
Am Heart J. 2007 Jul;154(1):87-93
pubmed: 17584559
BMJ. 2016 May 16;353:i2416
pubmed: 27184143
Circulation. 2014 Jun 24;129(25 Suppl 2):S49-73
pubmed: 24222018
Nat Rev Drug Discov. 2003 Jul;2(7):517-26
pubmed: 12815379
JAMA Intern Med. 2014 Dec;174(12):1964-71
pubmed: 25285455
Ann Intern Med. 2019 Jan 1;170(1):W1-W33
pubmed: 30596876
J Am Coll Cardiol. 2016 May 10;67(18):2118-2130
pubmed: 27151343
PLoS One. 2016 Oct 12;11(10):e0164688
pubmed: 27732641
J Clin Epidemiol. 2016 Oct;78:90-100
pubmed: 27045189
Circulation. 2014 Jun 24;129(25 Suppl 2):S76-99
pubmed: 24222015
Ann Intern Med. 2015 Feb 17;162(4):266-75
pubmed: 25686167
Circulation. 2016 Dec 6;134(23):1789-1791
pubmed: 27920070
Stat Med. 2012 Dec 20;31(29):3821-39
pubmed: 22807043
J Epidemiol Community Health. 2007 Jan;61(1):40-7
pubmed: 17183014
Circulation. 2016 Nov 8;134(19):1430-1440
pubmed: 27682885
Abdom Imaging. 2015 Jan;40(1):222-6
pubmed: 25015400
BMJ. 1997 Sep 13;315(7109):635-40
pubmed: 9310564
JAMA. 2014 Aug 20;312(7):749-50
pubmed: 25138340
Eur Heart J. 2003 Jun;24(11):987-1003
pubmed: 12788299
Ann Intern Med. 2015 Jan 6;162(1):W1-73
pubmed: 25560730
J Clin Lipidol. 2015 Sep-Oct;9(5):640-6.e2
pubmed: 26350809
Circulation. 2001 Jul 24;104(4):491-6
pubmed: 11468215
Heart. 2006 Dec;92(12):1752-9
pubmed: 16621883
Methods Inf Med. 2007;46(1):43-9
pubmed: 17224979
PLoS Med. 2014 Oct 14;11(10):e1001744
pubmed: 25314315
Ann Intern Med. 2015 Jan 6;162(1):55-63
pubmed: 25560714
Eur Heart J. 2003 Nov;24(21):1903-11
pubmed: 14585248
J Clin Epidemiol. 2008 Jan;61(1):76-86
pubmed: 18083464
Int J Cardiol. 2015 Apr 1;184:587-94
pubmed: 25769004
Lancet Diabetes Endocrinol. 2015 May;3(5):339-55
pubmed: 25819778
J Clin Epidemiol. 2015 Mar;68(3):279-89
pubmed: 25179855
Atherosclerosis. 2005 Jul;181(1):93-100
pubmed: 15939059
J Cardiovasc Transl Res. 2016 Jun;9(3):214-222
pubmed: 26960568
Stat Med. 2017 Dec 10;36(28):4529-4539
pubmed: 27891652
Stroke. 2012 Jul;43(7):1998-2027
pubmed: 22627990
Eur Heart J. 2017 Feb 21;38(8):586-594
pubmed: 28363217
BMC Med Res Methodol. 2017 Jul 14;17(1):103
pubmed: 28709404
Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45
pubmed: 24222016
BMJ Open. 2015 Oct 26;5(10):e008717
pubmed: 26503388
JAMA. 2014 Apr 9;311(14):1403-5
pubmed: 24682222
Med J Aust. 2003 Feb 3;178(3):113-6
pubmed: 12558481
Med Care. 2017 Sep;55(9):864-870
pubmed: 28763374
Am J Cardiol. 2007 Nov 1;100(9):1410-5
pubmed: 17950799
BMC Cardiovasc Disord. 2014 Nov 20;14:163
pubmed: 25410585
Clin Chem. 2014 Jan;60(1):88-97
pubmed: 24100805
JAMA. 2014 Apr 9;311(14):1416-23
pubmed: 24681960
Eur Heart J. 2017 Feb 21;38(8):598-608
pubmed: 27436865
Stat Methods Med Res. 2018 Jan;27(1):185-197
pubmed: 27460537
Hypertens Res. 2001 Nov;24(6):685-9
pubmed: 11768728
BMJ. 2017 Jan 5;356:i6460
pubmed: 28057641
Ann Intern Med. 2012 Sep 18;157(6):389-97
pubmed: 22986376
PLoS One. 2012;7(3):e34287
pubmed: 22470551
BMJ Open. 2019 Apr 1;9(4):e026160
pubmed: 30940759
Rev Esp Cardiol. 2007 May;60(5):476-85
pubmed: 17535758
J Clin Epidemiol. 2016 Jan;69:40-50
pubmed: 26142114
Ann Fam Med. 2011 Sep-Oct;9(5):431-8
pubmed: 21911762
JAMA. 2001 Jul 11;286(2):180-7
pubmed: 11448281
Intern Med J. 2016 Mar;46(3):339-46
pubmed: 26662342
JAMA. 2014 Apr 9;311(14):1406-15
pubmed: 24682252
Diagn Progn Res. 2017 Sep 26;1:15
pubmed: 31093544
Am J Epidemiol. 2010 Oct 15;172(8):971-80
pubmed: 20807737
Stat Med. 2004 Aug 30;23(16):2567-86
pubmed: 15287085